Over the span of seven decades, marine natural products (MNPs) and their synthetic congeners have been revitalised as a vigorous respiratory and robust platform for global pharmaceutical industry and drug led discovery programmes . Indeed, in 1950, Bergmann and his co-workers reported the first two marine compounds spongothymidine and spongouridine from the Caribbean marine sponge Cryptotethya crypta . Twenty years later, they have been synthetically optimized to furnish the first two clinically approved marine drugs, commercially known as cytarabine (Cytosar-U®, Depocyst®, approved by FDA in 1969 for cancer treatment) and vidarabine (Vira-A®, approved by FDA in 1976 as antiviral) .